BioMedNewsBreaks Archive - Page 197 of 199

TuesdayJan 21, 2020 10:28 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Receipt of U.S. FDA Fast Track Designation for Immunogene Therapy that Targets Lung Cancer

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, nonviral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced that the U.S Food and Drug Administration (FDA) has granted Fast Track Designation for Genprex’s Oncoprex(TM) immunogene therapy in combination with EGFR inhibitor osimertinib (AstraZeneca’s Tagrisso(R)). Tagrisso(R), with worldwide sales of $1.86 billion in 2018 and $2.31 billion in the first 9 months of 2019, is currently AstraZeneca’s highest grossing product for the treatment of non-small cell lung cancer (NSCLC) patients with EFGR mutations that progressed after treatment with osimertinib alone. Genprex has treated more…

FridayJan 17, 2020 3:32 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Aims to Commercialize AI-Driven Predictive Model of Ovarian Cancer in Q1 2020

Predictive Oncology (NASDAQ: POAI), a data and artificial-intelligence- (“AI”) driven, discovery-services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, recently issued an update regarding its groundbreaking CancerQuest 2020 initiative driven by its Helomics subsidiary (http://nnw.fm/y6fnc). Per the update, the company intends to have its first predictive model of ovarian cancer prepared for initial commercialization in the first quarter of 2020. An article discussing the company reads, “‘We believe that this effort will enhance our understanding of the molecular profiles of women with ovarian cancer by using the power of artificial intelligence to create predictive…

MondayJan 06, 2020 1:05 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Appointment of Pam Prior to its Board of Directors

Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced the unanimous appointment of Pam Prior, CPA, to its Board of Directors. According to the update, Prior is the founder and CEO of Priorities Group, Inc., a provider of CFO services to small and mid-sized businesses, and has approximately 35 years of previous experience in accounting, predominantly in management as a chief financial officer and controller. “Predictive Oncology is very fortunate to announce that Pam Prior is joining our Board…

MondayJan 06, 2020 11:05 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Plans to Present at Biotech Showcase(TM) 2020 in San Francisco

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, nonviral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced its plans to attend and present at the Biotech Showcase(TM) 2020, to be held at the Hilton San Francisco Union Square in San Francisco from January 13–15, 2020. Genprex’s President and COO, Julien Pham, MD, MPH, will lead its presentation, scheduled for Monday, January 13 at 11:30 a.m. PT (2:30 p.m. ET); Track: Yosemite C (Ballroom Level). In addition, Pham and the company’s CEO, Rodney Varner, will be available for one-on-one investor meetings. “We are…

ThursdayNov 21, 2019 9:32 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces $1.26M Registered Direct Offering

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, on Wednesday announced a registered direct offering of 3,167,986 shares of its common stock at a price of $0.40 each, for gross proceeds of about $1.26 million prior to deduction of commissions and offering expenses. In a concurrent private placement, Genprex agreed to issue unregistered warrants to purchase up to 3,167,986 shares to the investors in the registered direct offering. The warrants, which have an exercise price of $0.46 per share, will be exercisable six months from the issuance date and will expire after five years. The warrants will be exercisable for…

TuesdayNov 19, 2019 10:59 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Reports Preclinical Data Showing Positive Results for Treatment of Resistant Metastatic Lung Cancers

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced that its collaborators from The University of Texas MD Anderson Cancer Center (“MD Anderson”) presented positive preclinical data at the American Association of Cancer Research Tumor Immunology and Immunotherapy Meeting 2019. According to the update, the data shows positive results for the combination of TUSC2 immunogene therapy with an anti-PD1 antibody, pembrolizumab, and for the combination of TUSC2 immunogene therapy, pembrolizumab, and chemotherapy for the treatment of some of the most resistant metastatic lung cancers, including the KRAS and LKB1 mutations. “These data not only further support existing preclinical data…

MondayNov 04, 2019 10:58 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Issues Lung Cancer Prevention Measures in Support of Lung Cancer Awareness Month

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) today announced that it is publishing lung cancer prevention measures in an effort to educate the public, prevent new cases and raise awareness in support of November’s Lung Cancer Awareness Month. According to the update, each case is unique, but several preventative actions may lower the risk of lung cancer, including avoiding or quitting smoking, reducing exposure to secondhand smoke and radon, and knowing one’s familial history with lung cancer. Genprex is developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including its initial product candidate, Oncoprex(TM) immunogene…

WednesdayOct 09, 2019 9:44 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Plans to Present at Inaugural MicroCap Rodeo Investor Conference

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) today announced its plans to present at the upcoming inaugural MicroCap Rodeo Investor Conference to be held at the Hilton Austin - Downtown in Austin, Texas. Genprex’s presentation is scheduled to take place on Tuesday, October 15 at 9:10 a.m. Central Time, led by its Chairman and CEO Rodney Varner, who will also be available for one-on-one meetings with investors. In addition, the presentation will be available via live webcast, with an archived recording to be provided for later viewing. To view the full press release, visit http://nnw.fm/sISn1 About Genprex, Inc. Genprex, Inc.…

MondayOct 07, 2019 10:37 am

BioMedNewsBreaks – Genprex, Inc.’s (NASDAQ: GNPX) Pioneering Use of Non-Viral Vector Delivery for Gene Therapy Validated by Additional Industry Research

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) today announced additional research in the field validating non-viral vector delivery as the next evolution in gene therapy. Per the update, a recently published paper titled, “Encapsulation, Visualization and Expression of Genes with Biomimetically Mineralized Zeolitic Imidazolate Framework-8 (ZIF-8),” by researchers in Australia, Spain and Austria, supports the belief that non-viral delivery could be a safer alternative for patients than viral vectors, also potentially speeding production time while reducing costs. Genprex was not involved in the study that used a different nanotechnology. “One of the biggest differentiators between Genprex and other gene therapy…

WednesdaySep 25, 2019 10:48 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Highlighted in Editorial on Potential Breast Cancer Treatments

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced its placement in an editorial published by BioMedWire ("BMW"), a multifaceted financial news and publishing company for private and public entities. The publication, titled “Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers,” may be accessed via the following link: http://nnw.fm/pNKm2. The editorial reads,“‘Disruptive’ isn’t a term that’s often applied to medicine, where the aim is to avoid disrupting the health of the human body. But technology such as Genprex Inc.’s (NASDAQ: GNPX) Oncoprex(TM) immunogene therapy is disruptive precisely because it could improve doctors’ ability to preserve health. It may…

News and publishing service for medical and biotechnology related companies

Contact us: 415.949.5050

BioMedNewsBreaks

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Receipt of U.S. FDA Fast Track Designation for Immunogene Therapy that Targets Lung Cancer

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Aims to Commercialize AI-Driven Predictive Model of Ovarian Cancer in Q1 2020

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Appointment of Pam Prior to its Board of Directors

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Plans to Present at Biotech Showcase(TM) 2020 in San Francisco

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces $1.26M Registered Direct Offering

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Reports Preclinical Data Showing Positive Results for Treatment of Resistant Metastatic Lung Cancers

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Issues Lung Cancer Prevention Measures in Support of Lung Cancer Awareness Month

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Plans to Present at Inaugural MicroCap Rodeo Investor Conference

BioMedNewsBreaks – Genprex, Inc.’s (NASDAQ: GNPX) Pioneering Use of Non-Viral Vector Delivery for Gene Therapy Validated by Additional Industry Research

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Highlighted in Editorial on Potential Breast Cancer Treatments

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search